FDA records linked by MedtechLedger identify OrbusNeich Medical (Shenzhen) Co., Ltd. at #1 Jinkui Rd., Futian Free Trade Zone, Shenzhen, as the applicant for a peripheral balloon catheter cleared in September 2026. The filing describes a scoring balloon intended for percutaneous transluminal angioplasty, classified as a Class II percutaneous catheter in the cardiovascular advisory committee. The Shenzhen entity is distinct from OrbusNeich Medical Group Holdings Limited, the Hong Kong-listed group whose own reports and factsheet describe the broader corporate organization. [1][2][4][8]
The 2026 JADE SCORE clearance
K261778 covers the JADE SCORE PTA Scoring Balloon Dilatation Catheter, received May 29, 2026, and cleared September 16, 2026 under decision code SESE, meaning substantially equivalent. The clearance letter lists regulation 21 CFR 870.1250, regulatory Class II, product code PNO, and a Traditional clearance type with a summary statement. The FDA record lists the applicant city as Shenzhen and the advisory committee as Cardiovascular. [1][2]
The clearance letter states that the submitted information supports a determination of substantial equivalence between the JADE Score device and the predicate device described in the letter. The letter does not, in the available text, name that predicate. FDA guidance for peripheral PTA and specialty catheters notes that scoring and cutting balloons concentrate dilating forces along scoring elements or atherotomes and carry additional testing considerations beyond a standard PTA catheter. [2][9]
Earlier JADE PLUS filing
A June 11, 2024 clearance letter for K241025 names the same Shenzhen applicant and the JADE PLUS PTA Balloon Dilatation Catheter, also under 21 CFR 870.1250, Class II, but under product code LIT. That submission lists the JADE PTA Balloon Dilatation Catheter (K202231, LIT, cleared December 10, 2020) as primary predicate and states the predicate had not been subject to a design-related recall. The 2024 letter identifies Jerry Cheung as Senior Director of Regulatory Affairs; the 2026 letter identifies Dora Zhang as Manager of Regulatory Affairs. [6][2]
Applicant versus listed group
OrbusNeich Medical Group Holdings Limited, incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange under stock code 6929, publishes annual and interim reports and a corporate factsheet. The August 2026 factsheet describes a multinational device company focused on interventional devices for PCI and PTA procedures, headquartered in Hong Kong, selling in more than 70 countries and regions, and expanding into structural heart disease. Those statements come from the manufacturer’s own publications and describe the group, not the Shenzhen applicant’s FDA filings. [4][5][8]
The company website states a vision of improving quality of life for patients with vascular disease and lists CE, FDA and NMPA approved product sections. The factsheet organizes offerings around lesion access, preparation, optimization and therapy, including coronary balloons, coronary stents and peripheral balloons. These are company-published descriptions; the FDA records cited here document only the two JADE-family clearances. [7][8]
What the filing record shows
The linked collection contains one 510(k) record, K261778, with a decision count of one SESE and a sample decision count of one SESE; the sample and the collection are the same size here. This is an as-of snapshot of the filings provided, not a measure of total portfolio, sales or safety performance. No recall records appear in the collection. [1]

